Immuron (IMRN) Retained Earnings (2016 - 2025)
Immuron's quarterly Retained Earnings came in at -$824804.3 in Q3 2025, down 4.45% year-on-year from -$863193.9 in Q3 2024, and up 98.44% quarter-over-quarter from -$52.8 million in Q2 2025.
Immuron has reported Retained Earnings for 10 years, with the latest figure at -$824804.3 in Q3 2025.
- For the quarter ending Q3 2025, Retained Earnings fell 4.45% year-over-year to -$824804.3; the trailing twelve-month figure through Sep 2025 stood at -$824804.3 (down 4.45% YoY), and the FY2025 full-year result was -$824804.3, down 4.45% from the prior year.
- Retained Earnings for Q3 2025 stood at -$824804.3, up from -$52.8 million in the prior quarter.
- The five-year high for Retained Earnings was $422.6 billion in Q4 2024, with the low at -$52.8 million in Q2 2025.
- Average Retained Earnings over 5 years is $30.2 billion, with a median of -$22.9 million recorded in 2022.
- Year-over-year, Retained Earnings tumbled 7489.55% in 2021 and soared 87575294.61% in 2024.
- Tracing IMRN's Retained Earnings over 5 years: stood at -$48.0 million in 2021, then increased by 6.4% to -$45.0 million in 2022, then jumped by 98.93% to -$482570.0 in 2023, then soared by 87575294.61% to $422.6 billion in 2024, then sank by 100.0% to -$824804.3 in 2025.
- The last three Retained Earnings figures came in at -$824804.3 (Q3 2025), -$52.8 million (Q2 2025), and $422.6 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | -824,804.27 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | -824,804.27 |
| Jun 30, 2025 | -52.80 Mn |
| Dec 31, 2024 | 422.61 Bn |
| Sep 9, 2024 | -789,683.96 |
| Jun 30, 2024 | -52.04 Mn |
| Dec 31, 2023 | -482,569.99 |
| Sep 28, 2023 | -47.23 Mn |
| Aug 30, 2023 | -720,553.96 |
| Jun 30, 2023 | -48.16 Mn |
| Dec 31, 2022 | -44.96 Mn |
| Aug 31, 2022 | -47.58 Mn |
| Jun 30, 2022 | -684,252.81 |
| Dec 31, 2021 | -48.03 Mn |
| Jun 30, 2021 | -659,328.88 |
| Dec 31, 2020 | -632,871.95 |
| Sep 1, 2020 | -57.92 Mn |
| Jun 30, 2020 | -37.96 Mn |
| Dec 31, 2019 | -579,164.23 |
| Jun 30, 2019 | 3.01 Mn |
| Dec 31, 2018 | -52.54 Mn |
| Sep 27, 2018 | -38.45 Mn |
| Aug 30, 2018 | -52.54 Mn |
| Jun 30, 2018 | 2.34 Mn |
| Dec 31, 2017 | -38.60 Mn |
| Sep 28, 2017 | -39.06 Mn |
| Aug 31, 2017 | -49.53 Mn |
| Jun 30, 2017 | 1.86 Mn |
| Dec 31, 2016 | -32.29 Mn |
| Jun 30, 2016 | 1.59 Mn |